Physician profile
Shari Anthony
NPI 1447697099
$4,456.68
in general payments reported to CMS, 2019-2025
31 companies · $86.66 in 2025
The $86.66 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,764 · 2020: $116 · 2021: $219 · 2022: $479 · 2023: $820 · 2024: $973 · 2025: $86.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,865 · Entertainment: $13.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,865.20 |
| Entertainment | $13.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $738.90 | 2019-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $697.31 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $542.15 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.38 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $285.13 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $242.99 | 2019-2024 | Zepbound |
| Amgen INC. | $202.18 | 2019-2024 | Repatha, Otezla, Prolia |
| Glaxosmithkline, LLC. | $194.48 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $192.32 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $106.86 | 2019 | |
| Intuitive Surgical, INC. | $98.62 | 2022 | |
| Exact Sciences Corporation | $93.48 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $84.85 | 2019-2020 | |
| Gilead Sciences, INC. | $81.05 | 2019-2024 | |
| Viiv Healthcare Company | $78.95 | 2023-2024 | Apretude |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $72.98 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.12 | 2022 | |
| Abbott Laboratories | $50.07 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3, Proclaim |
| Merck Sharp & Dohme LLC | $48.30 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $38.03 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $33.55 | 2021 | |
| Sanofi Pasteur INC. | $26.03 | 2019 | |
| Almatica Pharma LLC | $22.70 | 2023 | Gralise |
| Amarin Pharma, INC. | $20.79 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2024 | |
| Dynavax Technologies Corporation | $19.62 | 2023 | Heplisav-B |
| Nevro Corp. | $18.41 | 2023 | Senza |
| Idorsia Pharmaceuticals US INC | $17.65 | 2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $17.43 | 2019 | |
| Ethicon US, LLC | $14.05 | 2019 | |
| Optos, INC. | $13.68 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.